Epilepsy Therapeutics Market in APAC - Size, Projections, Drivers, Trends, Vendors, and Analysis Through 2021 by Technavio

Technavio has published a new report on the epilepsy therapeutic market in APAC from 2017-2021. (Graphic: Business Wire)

LONDON--()--According to the latest market study released by Technavio, the epilepsy therapeutic market in APAC is projected to grow to USD 1,306.08 million by 2021, at a CAGR of more than 4% over the forecast period.

This research report titled ‘Epilepsy Therapeutic Market in APAC 2017-2021’ provides an in-depth analysis of the market in terms of revenue and emerging market trends. This market research report also includes up to date analysis and forecasts for various market segments and all geographical regions.

Epilepsy is a neurological condition characterized by the occurrence of two or more unprovoked seizures. The epilepsy therapeutics market in APAC is expected to post rapid growth during the forecast period. The lack of disease-modifying therapies, in addition to huge unmet needs for the same, is expected to drive the market growth.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

Based on the product type, the report categorizes the epilepsy therapeutic market in APAC into the following segments:

  • First-generation epilepsy therapeutics
  • Second-generation epilepsy therapeutics
  • Third-generation epilepsy therapeutics

First-generation epilepsy therapeutics

First-generation epilepsy therapeutics occupied more than 45% of the market in APAC, establishing itself as the dominant product. The first-generation antiepileptic drugs include benzodiazepines, carbamazepine, phenytoin, valproic acid, and phenobarbital,” says Sapna Jha, a lead analyst at Technavio for central nervous system research.

The high market share of the first-generation antiepileptic drugs (AEDs) is due to its established adoption among end-users owing to the first mover advantage in the market. However, the AEDs usually require close monitoring and may lead to life-threatening reactions, which is expected to lead to the eventual decline of the product segment.

Second-generation epilepsy therapeutics

The second-generation AEDs include drugs such as zonisamide, topiramate, gabapentin, pregabalin, felbamate, tiagabine, lamotrigine, and levetiracetam. The second-generation AEDs provide advantages such as simpler pharmacokinetic profiles, which will lead to a quick rise in their adoption over the coming years.

The market segment is boosted by the increasing availability of drugs with better safety and tolerability profile when compared to its predecessors. Additionally, the developed infrastructure in Japan and Australia coupled with the presence of major players such as Eisai, Daiichi Sankyo, and UCB are likely to drive the market growth further.

Third-generation epilepsy therapeutics

The third-generation AEDs include lacosamide, retigabine, and pregabalin. The third generation AEDs are intended to treat individuals who do not respond well to the previous generation of drugs. These drugs provide a better pharmacokinetic profile and less severe side effects.

“The third-generation epilepsy therapeutics market in APAC is expected to showcase a CAGR of nearly 7% through the forecast period, due to increasing partnership among established vendors to develop and market these drugs. The continuous efforts of vendors to satisfy the unmet need for disease-modifying drugs will also impact the market growth,” says Sapna.

The top vendors highlighted by Technavio’s research analysts in this report are:

  • Eisai
  • GlaxoSmithKline
  • Pfizer
  • UCB

Browse Related Reports:

Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like in-vitro diagnostics, infectious and rare diseases, and life science research tools. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, resellers, and end-users.

If you are interested in more information, please contact our media team at media@technavio.com.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770

Release Summary

According to the latest market study by Technavio, the epilepsy therapeutic market in APAC is projected to grow to USD 1,306.08 million by 2021.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770